financetom
Business
financetom
/
Business
/
Update: Boeing Begins Certification Flight Tests for Delayed 777-9 Aircraft
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Boeing Begins Certification Flight Tests for Delayed 777-9 Aircraft
Jul 16, 2024 2:48 AM

05:42 AM EDT, 07/16/2024 (MT Newswires) -- (Updates with details from Boeing's ( BA ) statement in the second paragraph and a response from the FAA in the fourth paragraph.)

Boeing ( BA ) conducted the first certification flight test for its long-delayed 777-9 plane on Friday under the oversight of the US Federal Aviation Administration, the company said in a post on X Saturday.

Boeing ( BA ) received a type inspection authorization from the FAA, the company confirmed to MT Newswires in an emailed statement. It expects the 777-9 to enter service next year, media outlets reported Monday.

"The 777-9 flight-test fleet will undergo the most thorough commercial flight-test effort Boeing ( BA ) has ever undertaken," Boeing ( BA ) said in its statement.

While the FAA declined to comment to MT Newswires regarding specific certification processes, a spokesperson said that "this kind of thorough process takes many months."

Price: 179.48, Change: +0.37, Percent Change: +0.21

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study
Kezar Life Sciences Gets Nod to Proceed With Autoimmune Hepatitis Trial; Ends Lupus Nephritis Study
Oct 17, 2024
02:44 PM EDT, 10/17/2024 (MT Newswires) -- Kezar Life Sciences ( KZR ) said Thursday the Independent Data Monitoring Committee has recommended the Portola phase 2a trial of zetomipzomib in patients with autoimmune hepatitis to proceed without modification following its review. Kezar said the trial, which is being conducted in the US, has so far not shown any grade 4...
Market Chatter: Microsoft-Backed OpenAI, Bain Expand Partnership to Sell AI Tools to Bain Clients
Market Chatter: Microsoft-Backed OpenAI, Bain Expand Partnership to Sell AI Tools to Bain Clients
Oct 17, 2024
02:44 PM EDT, 10/17/2024 (MT Newswires) -- Microsoft ( MSFT )-backed (MSFT) OpenAI and Bain are extending their partnership to sell OpenAI's ChatGPT and other AI tools to the consulting firm's clients, The Wall Street Journal reported Thursday. The companies started a sales partnership in 2023 and in August 13,000 Bain consultants got licenses for ChatGPT Enterprise, according to the...
Greenheart Gold Up 9.2% as it Completes a $36 Million Private Placement
Greenheart Gold Up 9.2% as it Completes a $36 Million Private Placement
Oct 17, 2024
02:31 PM EDT, 10/17/2024 (MT Newswires) -- Greenheart Gold ( GHRTF ) on Thursday said it closed a brokered private placement financing that raised $36 million as it placed 72.09-million shares priced at $0.50 each. Proceeds will be used to acquire properties mineral properties in Guyana and Suriname, for working capital and general corporate purposes. Greenheart Gold ( GHRTF )...
Immutep Completes Recruitment for Early-Stage Trial of IMP761, Advances to Dose Escalation
Immutep Completes Recruitment for Early-Stage Trial of IMP761, Advances to Dose Escalation
Oct 17, 2024
09:07 AM EDT, 10/17/2024 (MT Newswires) -- Immutep ( IMMP ) said Thursday that it has completed recruitment for the first part of its early-stage trial for IMP761, a LAG-3 immunotherapy aimed at treating autoimmune diseases. The part A, single dose, of the placebo-controlled, double-blind trial reported no safety issues following drug administration, the company said. The trial will now...
Copyright 2023-2026 - www.financetom.com All Rights Reserved